Unity Biotechnology's corporate restructuring is a cash-saving move that allows the company to focus resources on its lead program, a drug in Phase 2 testing for diabetic macular edema and wet age-related macular degeneration. Unity previously restructured in 2020 following the Phase 2 failure of its osteoarthritis drug.
At a time when a large portion of healthcare practitioner interactions have switched to digital, it's clear that life science companies need to transform their approach to be much more collaborative in the way they work with healthcare professionals.
A new survey from Reuters Events in collaboration with Microsoft and Exeevo, Medical-commercial collaborating to win in the digital era, offers an inside look at the trends and challenges with which life science professionals have to contend, and how they are responding and explores new strategies and tactics for how these companies are working with healthcare providers and adapting themselves to improve the patient experience in healthcare.
We are extending our INVEST 2022 Pitch Perfect deadline to Feb 11, 11:59 p.m. ET to allow interested startups to apply to the 4 tracks - PharmaTech, Diagnostics 2.0, Care Coordination and Value-Based Care, and Remote Patient Monitoring and Smart Devices. Slots are going fast so we encourage all startups - particularly those interested to apply in the PharmaTech and Diagnostics tracks to apply immediately. Selected startups will get to pitch LIVE on stage in front of VC judges. Here's the agenda for the INVEST conference.
Clinical-stage Arcellx raised $123.8 million from its IPO, which the company will use to advance to a pivotal test for its lead program, a CAR T-cell therapy for multiple myeloma. Though Arcellx trails its large pharmaceutical rivals, the biotech contends its technology produces cell therapies with key advantages.
No comments